Tag: Michael Vodicka

Sproutly Looking To Revolutionize The Cannabis Beverages Industry

Posted on by The INO.com Team

Analysis originally distributed on August 3, 2018 By: Michael Vodicka of Cannabis Stock Trades

Game-changing companies don’t come along very often. But when they do, shareholders usually see big gains.

This pattern continues to repeat itself in the stock market.

Netflix (NFLX) is a recent example.

Back in 2007, Netflix introduced a game changer in the home entertainment industry, releasing a new service that enabled customers to stream movies from the internet into their homes.

That innovation led to ridiculous gains for Netflix shareholders that completely crushed the broader stock market.

In just the last six years, Netflix has surged from $7.50 per share to a recent high above $400. That 5,000% return means that a $10,000 investment in Netflix in 2012 would be worth about $500,000 today.

Sproutly

These game changers are rare and hard to find. True game-changing technology doesn’t come around very often.

That’s why I’m excited about a new cannabis stock that reminds me of Netflix in 2007. Continue reading "Sproutly Looking To Revolutionize The Cannabis Beverages Industry" →

Promising Cannabis Biotech Jumps 23%

Posted on by The INO.com Team

Analysis originally distributed on July 11, 2018 By: Michael Vodicka of Cannabis Stock Trades

June 26 was a groundbreaking day for the US cannabis industry.

That’s the day the FDA, the US agency responsible for approving new drug candidates, approved its first-ever cannabis drug.

The first-ever medical treatment derived from a marijuana plant will hit the U.S. market in a few months after regulators on Monday gave the epilepsy treatment the green light.

The Food and Drug Administration approved GW Pharmaceuticals Plc’s Epidiolex to treat two rare forms of childhood epilepsy, according to a statement from the agency. The liquid is made from a compound in the marijuana plant called cannabidiol, a different chemical from tetrahydrocannabinol, or THC, which gets users high.

First Marijuana-Based Medicine Is Approved for Sale in U.S.

This ruling is important for two reasons. Continue reading "Promising Cannabis Biotech Jumps 23%" →

Molson Coors Eyeing Canadian Cannabis Partner

Posted on by The INO.com Team

Analysis originally distributed on June 28, 2018 By: Michael Vodicka of Cannabis Stock Trades

October 30, 2017 was one of the best days of the year for the young cannabis industry.

That’s the date when Constellation Brands (STZ), the second-largest US beer maker, announced a 10% stake in Canopy Growth Corp. (CGC/WEED), the largest Canadian cannabis company.

It was a groundbreaking moment for the cannabis industry because it was the first time that a big alcohol company had invested directly in a cannabis company.

Not only did it give the young cannabis industry tons of credibility, it also sets the stage for big alcohol to invest billions into the cannabis industry in the next few years.

In the short run, Canopy shares jumped more than 23% in one day on the news.

In the long run, it triggered a 10-week rally in Canopy – and the entire cannabis sector – that sent shares deep into a new all-time high. Take a look. Continue reading "Molson Coors Eyeing Canadian Cannabis Partner" →

A New Entry Into Germany’s Cannabis Industry

Posted on by The INO.com Team

Analysis originally distributed on June 21, 2018 By: Michael Vodicka of Cannabis Stock Trades

Germany has quickly emerged as one of the fastest-growing medical cannabis markets in the world.

According to a study on the German health insurance market, 500 German patients requested medical cannabis in January of 2017.

In December of the same year, the number of patients requesting reimbursements for cannabis prescriptions skyrocketed to 13,000.

What was the biggest factor that drove the huge spike?

German insurance companies started covering medical cannabis subscriptions in 2017 – and the number of patients surged.

Looking forward – this bullish trend is expected to accelerate.

Tens of thousands of new patients are expected to enroll in Germany’s medical cannabis program in 2018.

Longer term – I expect the success of Germany’s medical cannabis market to usher in recreational legalization. Continue reading "A New Entry Into Germany’s Cannabis Industry" →

Leading Cannabis Biotech Could Soar

Posted on by The INO.com Team

Analysis originally distributed on Juney 13, 2018 By: Michael Vodicka of Cannabis Stock Trades

Blockbuster drugs are the holy grail of the pharmaceutical industry.

When annual sales of a hot new drug break the $1 billion mark, investors are usually rewarded with big gains.

This is what began happening in 2012 with Gilead Sciences Inc. (GILD).

In 2013, the FDA approved Gilead’s hepatitis C drug Sovaldi.

In 2014, Gilead scored an FDA approval for another Hep C drug, Harvoni.

Both drugs went on to quickly hit blockbuster status – sending shares of Gilead soaring – jumping more than 200% in the next two years.

Cannabis Biotech

Today, the young cannabis industry is in hot pursuit of its first-ever cannabis blockbuster – and it looks like a winner could be crowned on June 27. Continue reading "Leading Cannabis Biotech Could Soar" →